Equillium (EQ) Competitors $0.39 0.00 (-0.05%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.75%) As of 09:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. DTIL, IKNA, KPTI, RENB, ARTV, OTLK, VNRX, PEPG, ATNM, and STTKShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Precision BioSciences (DTIL), Ikena Oncology (IKNA), Karyopharm Therapeutics (KPTI), Renovaro (RENB), Artiva Biotherapeutics (ARTV), Outlook Therapeutics (OTLK), VolitionRx (VNRX), PepGen (PEPG), Actinium Pharmaceuticals (ATNM), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Precision BioSciences Ikena Oncology Karyopharm Therapeutics Renovaro Artiva Biotherapeutics Outlook Therapeutics VolitionRx PepGen Actinium Pharmaceuticals Shattuck Labs Precision BioSciences (NASDAQ:DTIL) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, community ranking, analyst recommendations and institutional ownership. Which has preferable valuation & earnings, DTIL or EQ? Equillium has lower revenue, but higher earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrecision BioSciences$68.70M0.71-$61.32M-$2.01-2.31Equillium$41.10M0.33-$13.34M-$0.23-1.67 Do analysts prefer DTIL or EQ? Precision BioSciences currently has a consensus price target of $47.00, indicating a potential upside of 910.75%. Equillium has a consensus price target of $3.00, indicating a potential upside of 679.02%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders & institutionals believe in DTIL or EQ? 38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 27.0% of Equillium shares are owned by institutional investors. 4.5% of Precision BioSciences shares are owned by company insiders. Comparatively, 31.6% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, DTIL or EQ? Precision BioSciences has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500. Comparatively, Equillium has a beta of 2.06, suggesting that its stock price is 106% more volatile than the S&P 500. Does the media refer more to DTIL or EQ? In the previous week, Precision BioSciences had 2 more articles in the media than Equillium. MarketBeat recorded 2 mentions for Precision BioSciences and 0 mentions for Equillium. Equillium's average media sentiment score of 0.00 beat Precision BioSciences' score of -0.31 indicating that Equillium is being referred to more favorably in the news media. Company Overall Sentiment Precision BioSciences Neutral Equillium Neutral Does the MarketBeat Community prefer DTIL or EQ? Precision BioSciences received 60 more outperform votes than Equillium when rated by MarketBeat users. However, 80.00% of users gave Equillium an outperform vote while only 69.06% of users gave Precision BioSciences an outperform vote. CompanyUnderperformOutperformPrecision BioSciencesOutperform Votes9669.06% Underperform Votes4330.94% EquilliumOutperform Votes3680.00% Underperform Votes920.00% Is DTIL or EQ more profitable? Precision BioSciences has a net margin of 11.48% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets Precision BioSciences11.48% -23.69% -6.98% Equillium -10.05%-20.68%-10.77% SummaryPrecision BioSciences beats Equillium on 11 of the 18 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.76M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-2.758.9226.7619.71Price / Sales0.33252.24389.71117.54Price / CashN/A65.8538.2534.62Price / Book0.606.466.784.50Net Income-$13.34M$143.98M$3.23B$248.18M7 Day Performance-1.26%2.03%1.51%0.23%1 Month Performance-17.18%4.11%10.03%12.39%1 Year Performance-73.07%-2.87%16.65%7.07% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium2.6318 of 5 stars$0.39-0.1%$3.00+679.0%-74.5%$13.76M$41.10M-2.7540DTILPrecision BioSciences3.4772 of 5 stars$5.22+1.8%$47.00+800.4%-64.4%$55.07M$68.70M87.01200Earnings ReportAnalyst ForecastIKNAIkena Oncology2.8393 of 5 stars$1.14+0.9%$3.00+163.2%-16.7%$55.01M$659,000.00-0.9370Positive NewsKPTIKaryopharm Therapeutics3.8339 of 5 stars$6.15+2.3%$57.50+835.0%-72.0%$52.71M$145.24M-6.03380Gap DownRENBRenovaro0.8116 of 5 stars$0.32+2.4%N/A-69.9%$51.30MN/A-0.3520ARTVArtiva Biotherapeutics1.7053 of 5 stars$2.10+1.0%$20.40+871.4%N/A$51.16M$251,000.000.0081OTLKOutlook Therapeutics1.9942 of 5 stars$1.59+3.9%$10.20+541.5%-79.3%$50.91MN/A-0.2120Earnings ReportVNRXVolitionRx1.8979 of 5 stars$0.49-1.0%$3.33+573.7%-29.0%$49.86M$1.23M-1.3780Gap UpPEPGPepGen3.1313 of 5 stars$1.51+0.7%$9.67+540.2%-89.6%$49.41MN/A-0.5130Gap UpATNMActinium Pharmaceuticals1.2083 of 5 stars$1.55+4.7%$4.00+158.1%N/A$48.35M$81,000.00-1.1230Trending NewsSTTKShattuck Labs2.5735 of 5 stars$0.99+4.4%$7.50+657.6%-86.1%$47.42M$4.61M-0.65100Gap Up Related Companies and Tools Related Companies Precision BioSciences Competitors Ikena Oncology Competitors Karyopharm Therapeutics Competitors Renovaro Competitors Artiva Biotherapeutics Competitors Outlook Therapeutics Competitors VolitionRx Competitors PepGen Competitors Actinium Pharmaceuticals Competitors Shattuck Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EQ Stock Free EQ Stock Alerts